Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

2026 Radionuclide Theranostics for the Management of Cancer Gordon Research Conference and Gordon Research Seminar

Award Number: R13CA314215
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

2026 Radionuclide Theranostics for the Management of Cancer Gordon Research Conference and Gordon Research Seminar - PROJECT SUMMARY The 2026 Gordon Research Conference (GRC) on Radionuclide Theranostics for the Management of Cancer, along with the preceding Gordon Research Seminar (GRS), is a premier scientific meeting designed to advance the field of radionuclide-based diagnostics and therapeutics for cancer treatment. Set within the retreat-style format of GRC, the conference will convene a diverse, interdisciplinary community of academic and industry scientists, physicists, oncologists, clinicians, and regulatory leaders to address critical barriers limiting the clinical translation, global accessibility, and optimal use of theranostics in cancer medicine. The objectives of the conference are fourfold: foster cross-disciplinary collaboration, accelerate translational research, support early- career scientists, and promote scientific rigor through the exchange of unpublished data and open dialogue. The meeting’s theme, “Theranostics Reimagined: Interrogating Biology, Empowering Translation,” reflects its focus on three foundational challenges: limited access to radioligand therapies worldwide, the complexity of cancer biology and patient stratification, and gaps in understanding dosimetry, immunologic interactions, and enhanced targeting strategies that lead to improved efficacy. These objectives will be met through nine formal topical sessions, poster presentations, provocative discussions, and dedicated networking opportunities that encourage interactive engagement among participants. The GRS will provide a dedicated platform for trainees to present cutting-edge research and receive mentorship. With its progressive agenda and intimate format, this GRC is uniquely positioned to shape the future of radionuclide theranostics and precision oncology, and aligns closely with National Cancer Institute’s mission to improve outcomes and quality of life for patients through research- driven advances in cancer care.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $4,000 )
2026	2026	GORDON RESEARCH CONFERENCES	5586 POST RD UNIT 2	EAST GREENWICH	RI	02818	KENT	USA	Cancer Treatment Research	000	1	5/4/2026	NEW	$4,000
														Subtotal = $4,000

Grand Total All Awards = $4,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

2026 Radionuclide Theranostics for the Management of Cancer Gordon Research Conference and Gordon Research Seminar

Award Number: R13CA314215

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer